Get the Stockscreener App
42.39
10.10%
3.89
After Hours:
43.05
0.66
+1.56%
Moderna Inc stock is traded at $42.39, with a volume of 13.26M.
It is up +10.10% in the last 24 hours and up +7.07% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$38.50
Open:
$38.4
24h Volume:
13.26M
Relative Volume:
1.50
Market Cap:
$14.59B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-7.2835
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
+25.56%
1M Performance:
+7.07%
6M Performance:
-65.04%
1Y Performance:
-58.41%
1-Day Range:
$36.99
$42.54
1-Week Range:
$33.60
$42.54
52-Week Range:
$31.94
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
42.39 | 14.59B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.73 | 110.00B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.64 | 74.82B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
652.19 | 38.43B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.54 | 34.12B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.12 | 27.56B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna's Norovirus Vaccine Developments Amid U.S. OutbreakNews and Statistics - IndexBox, Inc.
A norovirus vaccine could be on the horizon as cases rise - CNBC
Why I Don’t Believe Larry Ellison’s Moderna Stock Hype - TipRanks
Is Larry Ellison Moderna's Saving Grace? Is Moderna Stock Now A Buy? - Yahoo! Voices
Moderna’s Stock (NASDAQ: MRNA) a Notable Gainer on Funding News - AskTraders
Moderna Target of Unusually Large Options Trading (NASDAQ:MRNA) - MarketBeat
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine - Infectious Disease Advisor
Why Moderna, Inc. (MRNA) Soared on Wednesday - Insider Monkey
Moderna (MRNA) Surges on AI-Driven Cancer Vaccine Potential - GuruFocus.com
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines - Yahoo News UK
HHS Provides $590 Million to Moderna for Pandemic Influenza Vaccine Development - MyChesCo
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines - Yahoo! Voices
Moderna Shares Are Up Today: What's Going On? - Benzinga
After a Reset Year, Is Moderna Stock Poised for a Comeback? - MSN
Moderna Surged Nearly 10% With a $590M Payday - Yahoo Finance
Moderna (NASDAQ:MRNA) Trading 11.4% HigherShould You Buy? - MarketBeat
Moderna (MRNA) Surges after Oracle’s Larry Ellison Praises AI-Driven Cancer Vaccines - TipRanks
Stock Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna stock up as Oracle's Ellison touts AI-led shots (MRNA) - Seeking Alpha
These 3 Stocks Are Down to Start 2025. What's Going On? - The Motley Fool
Moderna stock jumps on AI healthcare prospects - MSN
Moderna receives $590M from HHS to develop bird flu vaccine - McKnight's Senior Living
Moderna shoots higher on AI hopes - Sherwood News
Moderna Unusual Options Activity For January 22 - Benzinga
Moderna, Inc. (NASDAQ:MRNA) institutional owners may be pleased with recent gains after 65% loss over the past year - Yahoo Finance
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine - Benzinga
Moderna Gets $590 Million From U.S. to Accelerate Bird Flu Vaccine - Barron's
Top Stock Movers Now: Moderna, 3M, Walgreens, and More - MSN
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump - MSN
Moderna (NASDAQ:MRNA) Shares Gap UpShould You Buy? - MarketBeat
Why Is Moderna Stock Trading Higher On Tuesday? - Benzinga
Moderna gets $590M from US government for bird flu vaccine - BioPharma Dive
Where Will Moderna Be in 3 Years? - sharewise
Moderna Receives $590M From HHS To Develop Bird Flu Vaccine - messenger-inquirer
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine - MSN
Underperforming Moderna Stock Boosted by Bird Flu Vaccine - Schaeffers Research
Why Moderna (MRNA) Stock Is Advancing Today - Yahoo Finance
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development - Newsweek
$590 Million Supports Pre-Pandemic mRNA-based Vaccine Development - Vax-Before-Travel
These Stocks Are Moving the Most Today: Tesla, Apple, Moderna, Walgreens, Netflix, and More - Yahoo! Voices
Why Moderna, Inc. (MRNA) Crashed Last Week - MSN
Stocks to Watch Tuesday: MicroStrategy, Trump Media, Moderna, Walgreens - The Wall Street Journal
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab - MSN
$590m to Moderna from HHS for mRNA ‘flu vax development - Yahoo! Voices
Moderna to receive $590m from HHS for mRNA influenza vaccines - Pharmaceutical Technology
Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine - News & Insights
Moderna Awarded $590 Million To Develop Bird Flu Vaccine - Baystreet.ca
Dept. of Health Services awards Moderna $590 million to develop flu vaccines, bird flu vaccine - WSB Radio
Moderna wins US govt award for mRNA vaccine development - The Pharma Letter
Jim Cramer Says Moderna, Inc. (MRNA) Has Been ‘One Of The Biggest Disappointments Of The Year’ - Insider Monkey
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership - Seeking Alpha
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):